The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...

In a report released today, James Gordon from J.P. Morgan reiterated a Sell rating on GlaxoSmithKline (GSK – Research Report). The company’s ...

Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

Biotech company 23andMe had a rough 2024, including a $30 million settlement payment after customer data was compromised.

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.